Medicus Pharma Ltd

Medicus Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Company Highlights CD228V as its Principal Development Priority, Proposed SPAC Business Combination at ~ $135 Million Valuation for SkinJect® and…